Pomalidomide

• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended
  2023-503467-41-00 Phase III 9 countries Janssen - Cilag International
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended
  2024-518304-53-00 Phase III 6 countries European Myeloma Network B.V.
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended
  2023-503441-55-00 Phase II 10 countries Janssen - Cilag International
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended
  2023-509208-14-00 Phase III 13 countries Pfizer Inc.
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended
  2023-506877-37-00 Phase III 7 countries Glaxosmithkline Research & Development Limited
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended
  2023-508962-14-00 Phase III 10 countries Glaxosmithkline Research & Development Limited
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended
  2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
• Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended
  2023-509550-55-00 Phase I (FiH) 4 countries Glaxosmithkline Research & Development Limited
• A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended
  2023-506733-30-00 Phase II 1 country Fondazione European Myeloma Network Italy O.N.L.U.S.
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject… Ended
  2023-506112-40-00 Phase III 7 countries AbbVie Deutschland GmbH & Co. KG
• Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells f… Ended
  2024-516908-42-00 Phase II 1 country Fundacion PETHEMA
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended
  2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
• ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refr… Ended
  2024-516670-29-00 Phase II 1 country Centre Hospitalier Universitaire De Poitiers
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended
  2023-509472-42-00 Phase III 14 countries Celgene International II S.a.r.l.
• IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reac… Ended
  2024-513887-25-00 Phase II 1 country Intergroupe Francophone Du Myelome

Showing 25–40 of 40 trials